2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|March 15, 2016
- Pharmaceutical Technology-03-15-2016
- Volume 2016 eBook
- Issue 1
Excipient Quality and Selection
Author(s)Irwin Silverstein, PhD
The author discusses key areas of focus and presents best practices from the International Pharmaceutical Excipients Council (IPEC).
Advertisement
Defining quality for excipients may not be as clear cut as it is for APIs, but it is essential to product quality and patient safety, and to choosing the best supplier. The author discusses key areas of focus and presents best practices from the International Pharmaceutical Excipients Council (IPEC).
from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.
View other articles in the
.
Articles in this issue
over 10 years ago
Optimizing Tablet Compressionover 10 years ago
Filling the Analysis Gap in the Move to Continuous Processingover 10 years ago
Modeling and Simulation Move Downstreamover 10 years ago
Unifying Excipient Databasesover 10 years ago
Establishing a New Performance Standard for HPMC CapsulesAdvertisement
Related to this article
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Advertisement
Advertisement